Terms: = Pancreatic cancer AND IDH1, IDP, 3417, ENSG00000138413, IDH, PICD, O75874 AND Treatment
18 results:
1. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
2. Detecting undetectable - epidemiology, etiology, and diagnosis of carcinoma of unknown primary - systematic review.
Ostojewska J; Wieczorek I; Pachciński O; Zdziennicki W; Burdan F
Folia Med Cracov; 2023 Apr; 63(1):19-37. PubMed ID: 37406274
[TBL] [Abstract] [Full Text] [Related]
3. Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer.
Vera R; Ibarrola-de Andrés C; Adeva J; Pérez-Rojas J; García-Alfonso P; Rodríguez-Gil Y; Macarulla T; Serrano-Piñol T; Mondéjar R; Madrigal-Rubiales B
Rev Esp Patol; 2023; 56(1):32-44. PubMed ID: 36599598
[TBL] [Abstract] [Full Text] [Related]
4. Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer.
Vera R; Ibarrola-de-Andrés C; Adeva J; Pérez-Rojas J; García-Alfonso P; Rodríguez-Gil Y; Macarulla T; Serrano-Piñol T; Mondéjar R; Madrigal-Rubiales B
Clin Transl Oncol; 2022 Nov; 24(11):2107-2119. PubMed ID: 36008616
[TBL] [Abstract] [Full Text] [Related]
5. Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary cancers Treated With Platinum-Based Chemotherapy.
Uson Junior PLS; Majeed U; Yin J; Botrus G; Sonbol MB; Ahn DH; Starr JS; Jones JC; Babiker H; Inabinett SR; Wylie N; Boyle AWR; Bekaii-Saab TS; Gores GJ; Smoot R; Barrett M; Nagalo B; Meurice N; Elliott N; Petit J; Zhou Y; Arora M; Dumbauld C; Barro O; Baker A; Bogenberger J; Buetow K; Mansfield A; Mody K; Borad MJ
JCO Precis Oncol; 2022 Jun; 6(1):e2100274. PubMed ID: 35666960
[TBL] [Abstract] [Full Text] [Related]
6. BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme.
Xavier MA; Rezende F; Titze-de-Almeida R; Cornelissen B
Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439854
[TBL] [Abstract] [Full Text] [Related]
7. Early-Onset Pancreas cancer: Clinical Descriptors, Genomics, and Outcomes.
Varghese AM; Singh I; Singh R; Kunte S; Chou JF; Capanu M; Wong W; Lowery MA; Stadler ZK; Salo-Mullen E; Saadat LV; Wei AC; Reyngold M; Basturk O; Benayed R; Mandelker D; Iacobuzio-Donahue CA; Kelsen DP; Park W; Yu KH; O'Reilly EM
J Natl Cancer Inst; 2021 Sep; 113(9):1194-1202. PubMed ID: 33755158
[TBL] [Abstract] [Full Text] [Related]
8. Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with idh1-Mutant Solid Tumors.
Wick A; Bähr O; Schuler M; Rohrberg K; Chawla SP; Janku F; Schiff D; Heinemann V; Narita Y; Lenz HJ; Ikeda M; Ando Y; Wick W; Steinbach JP; Burger MC; Wenger K; Lassen U; Sankhala KK; Roggia C; Genvresse I; Munhoz C; Rentzsch C; Reschke S; Langer S; Wagner M; Kaulfuss S; Cai C; Lagkadinou E; Jeffers M; Peña C; Tabatabai G
Clin Cancer Res; 2021 May; 27(10):2723-2733. PubMed ID: 33622704
[TBL] [Abstract] [Full Text] [Related]
9. New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma.
Massironi S; Pilla L; Elvevi A; Longarini R; Rossi RE; Bidoli P; Invernizzi P
Cells; 2020 Mar; 9(3):. PubMed ID: 32168869
[TBL] [Abstract] [Full Text] [Related]
10. Targeting the Stress-Induced Protein NUPR1 to Treat pancreatic Adenocarcinoma.
Santofimia-Castaño P; Xia Y; Peng L; Velázquez-Campoy A; Abián O; Lan W; Lomberk G; Urrutia R; Rizzuti B; Soubeyran P; Neira JL; Iovanna J
Cells; 2019 Nov; 8(11):. PubMed ID: 31744261
[TBL] [Abstract] [Full Text] [Related]
11. Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4.
Masetti M; Acquaviva G; Visani M; Tallini G; Fornelli A; Ragazzi M; Vasuri F; Grifoni D; Di Giacomo S; Fiorino S; Lombardi R; Tuminati D; Ravaioli M; Fabbri C; Bacchi-Reggiani ML; Pession A; Jovine E; de Biase D
Cancer Biomark; 2018 Feb; 21(2):323-334. PubMed ID: 29103024
[TBL] [Abstract] [Full Text] [Related]
12. Posttranscriptional Upregulation of idh1 by HuR Establishes a Powerful Survival Phenotype in pancreatic cancer Cells.
Zarei M; Lal S; Parker SJ; Nevler A; Vaziri-Gohar A; Dukleska K; Mambelli-Lisboa NC; Moffat C; Blanco FF; Chand SN; Jimbo M; Cozzitorto JA; Jiang W; Yeo CJ; Londin ER; Seifert EL; Metallo CM; Brody JR; Winter JM
Cancer Res; 2017 Aug; 77(16):4460-4471. PubMed ID: 28652247
[TBL] [Abstract] [Full Text] [Related]
13. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct idh-Mutant Molecular Profiles.
Farshidfar F; Zheng S; Gingras MC; Newton Y; Shih J; Robertson AG; Hinoue T; Hoadley KA; Gibb EA; Roszik J; Covington KR; Wu CC; Shinbrot E; Stransky N; Hegde A; Yang JD; Reznik E; Sadeghi S; Pedamallu CS; Ojesina AI; Hess JM; Auman JT; Rhie SK; Bowlby R; Borad MJ; ; Zhu AX; Stuart JM; Sander C; Akbani R; Cherniack AD; Deshpande V; Mounajjed T; Foo WC; Torbenson MS; Kleiner DE; Laird PW; Wheeler DA; McRee AJ; Bathe OF; Andersen JB; Bardeesy N; Roberts LR; Kwong LN
Cell Rep; 2017 Mar; 18(11):2780-2794. PubMed ID: 28297679
[TBL] [Abstract] [Full Text] [Related]
14. Identification of a novel metabolic-related mutation (idh1) in metastatic pancreatic cancer.
Brody JR; Yabar CS; Zarei M; Bender J; Matrisian LM; Rahib L; Heartwell C; Mason K; Yeo CJ; Peiper SC; Jiang W; Varieur K; Madhavan S; Petricoin E; Fortuna D; Curtis M; Wang ZX; Pishvaian MJ; Winter JM
Cancer Biol Ther; 2018 Apr; 19(4):249-253. PubMed ID: 27466707
[TBL] [Abstract] [Full Text] [Related]
15. A high-throughput fluorimetric assay for 2-hydroxyglutarate identifies Zaprinast as a glutaminase inhibitor.
Elhammali A; Ippolito JE; Collins L; Crowley J; Marasa J; Piwnica-Worms D
Cancer Discov; 2014 Jul; 4(7):828-39. PubMed ID: 24740997
[TBL] [Abstract] [Full Text] [Related]
16. Genomic and transcriptional alterations of cholangiocarcinoma.
Ito T; Sakurai-Yageta M; Goto A; Pairojkul C; Yongvanit P; Murakami Y
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):380-7. PubMed ID: 24532422
[TBL] [Abstract] [Full Text] [Related]
17. The CpG island methylator phenotype: what's in a name?
Hughes LA; Melotte V; de Schrijver J; de Maat M; Smit VT; Bovée JV; French PJ; van den Brandt PA; Schouten LJ; de Meyer T; van Criekinge W; Ahuja N; Herman JG; Weijenberg MP; van Engeland M
Cancer Res; 2013 Oct; 73(19):5858-68. PubMed ID: 23801749
[TBL] [Abstract] [Full Text] [Related]
18. Frequent mutation of isocitrate dehydrogenase (idh)1 and idh2 in cholangiocarcinoma identified through broad-based tumor genotyping.
Borger DR; Tanabe KK; Fan KC; Lopez HU; Fantin VR; Straley KS; Schenkein DP; Hezel AF; Ancukiewicz M; Liebman HM; Kwak EL; Clark JW; Ryan DP; Deshpande V; Dias-Santagata D; Ellisen LW; Zhu AX; Iafrate AJ
Oncologist; 2012; 17(1):72-9. PubMed ID: 22180306
[TBL] [Abstract] [Full Text] [Related]
